Eton Pharmaceuticals, Inc.
ETON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | 1.34 | -0.02 | 0.59 |
| FCF Yield | 0.27% | 5.38% | 2.87% | -7.38% |
| EV / EBITDA | -248.04 | -331.06 | -9.42 | -89.59 |
| Quality | ||||
| ROIC | -4.64% | -7.76% | -45.69% | -9.31% |
| Gross Margin | 60.01% | 66.56% | 67.38% | 87.99% |
| Cash Conversion Ratio | -0.25 | -7.28 | -0.53 | 2.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.44% | 13.17% | 716.78% | 183.42% |
| Free Cash Flow Growth | -84.39% | 197.10% | 125.48% | 64.37% |
| Safety | ||||
| Net Debt / EBITDA | -10.33 | 54.93 | 1.51 | 6.88 |
| Interest Coverage | -1.30 | -1.12 | -8.65 | -1.49 |
| Efficiency | ||||
| Inventory Turnover | 1.02 | 11.61 | 12.45 | 4.77 |
| Cash Conversion Cycle | 309.05 | 7.02 | -31.84 | -78.86 |